Halozyme Therapeutics, Inc. (NASDAQ:HALO) was founded in 1998 and is headquartered in San Diego, California, USA, with 216 full-time employees. It is a biotechnology company dedicated to research, development and commercialization of human proteases.
Halozyme Therapeutics (HALO):
Halozyme Therapeutics is a biopharmaceutical company whose human enzymes are used to promote the delivery of injected drugs and fluids, enhance the effectiveness and absorption of other drugs, and can also be used to clinically change abnormal tissue structures. Olozmei Medical’s products are developed based on its proprietary “human recombinant hyaluronidase (rHuPH20)” Enhanze technology platform, which enables injectable biologics (including monoclonal antibodies and other therapeutic molecules, as well as small molecules). And fluids) can be delivered subcutaneously. Company products include:
- Hylenex recombinant-a preparation of rHuPH20 to facilitate the realization of hydrated subcutaneous infusion; improve dispersion and the absorption of other injected drugs; subcutaneous urography; improve the absorption of radiopaque agents.
- PEGPH20 is currently in the phase II clinical trial phase for the treatment of metastatic pancreatic cancer and the phase I clinical trial phase for the treatment of non-small cell lung cancer.
At present, Olozmei Medical has entered into partnerships with many well-known pharmaceutical companies to develop its ENHANZE™ drug delivery platform, including: F. Hoffmann-La Roche, Ltd. , Hoffmann-La Roche, Inc., Baxter Healthcare Corporation , Pfizer Inc. , Janssen Biotech, Inc., Nei Keta treatment (Nektar Therapeutics), Eisai Co., Ltd., AbbVie and Lilly so on.